#China #financial results #Changzhou #fiscal year 2026 #Jin Medical

Jin Medical International Ltd. Releases Financial Results for H1 Fiscal Year 2026

Overview
Jin Medical International Ltd. (NASDAQ: ZJYL), a leading provider of rehabilitation medical equipment in China, announced its unaudited financial results for the first half of fiscal year 2026, highlighting both challenges and progress within its operations. The report, released on August 4, 2026, reflects the financial period ending March 31, 2026.

Highlights of Financial Performance
During this period, Jin Medical experienced a revenue contraction of 9.7%, bringing total revenue down to $8.9 million compared to $9.9 million the previous year. The slowdown has been attributed to lower sales across its product range, primarily impacting other products and orders from its significant Japanese client, Nissin. Despite these challenges, the company maintained stable revenue from its core wheelchair products, with gross margin improving to 26.9% due to better inventory management practices.

CEO Erqi Wang remarked on the financial position of the company stating that even with a net loss of $0.2 million this half, the company holds a solid financial foundation with $9.1 million in cash and $21.0 million in short-term investments as of March 31, 2026. This fiscal stability positions Jin Medical to focus on enhancing product innovation and expanding its market reach.

Analysis of Revenue Sources
Revenue from wheelchair products showed a slight decline of 1.4%, generating $7.1 million, largely due to decreased sales to Nissin, which faced challenges due to fluctuating currency exchange rates. The revenue from wheelchair components saw a 9.9% increase, totaling $1.1 million, reflecting heightened demand for parts likely tied to maintenance and repairs. In stark contrast, the revenue from other product lines dwindled significantly, plunging 59.1% to just $0.7 million. Notably, this decline was influenced by issues regarding electric scooters, whose sales ceased due to the failure to secure necessary qualifications.

Cost Management and Profitability
The cost of revenue experienced a decrease of 12.8%, lowering to $6.5 million, which coupled with a gross profit stabilizing at $2.4 million suggests the company is effectively managing its operational expenses amidst challenging market conditions. Gross margin improvements are attributed to reduced variable costs related to their wheelchair product lines compared to the previous year.

Operating expenses grew modestly by 3.4% to $3.0 million, with research and development expenses seeing a notable rise of 33.4%. This increase indicates a commitment to driving future growth through product innovation.

Future Outlook
Looking ahead, Jin Medical aims to reinforce its core product offerings and broaden its customer base both domestically and internationally. The company is poised to escalate its production capabilities while maintaining disciplined management of costs and working capital to navigate foreseeable market volatility.

With an established operational infrastructure, including two manufacturing plants and a new facility under construction, the robustness of its product design and strategic focus on R&D underpins Jin Medical's vision for sustained growth in the competitive landscape of rehabilitation equipment.

For comprehensive updates and further information about Jin Medical's ongoing initiatives and product innovations, please visit Jin Medical's website.